

分類	一般名	商品名	使用濃度	消毒対象	備考	
ヨウ素系(中)	消毒用エタノール	消毒用エタノール	原液	手指	①粘膜や損傷皮膚には禁忌 ②傷や手荒れがある手指には用いない(刺激性がある) ③引火性に注意! ④即効性がある ⑤蒸発しやすく持続効果はない	
	70%イソプロパノール	消毒用イソプロ 70 消毒用イソプロピルアルコール 70 70%イソプロパノール 70%イソプロ 70%イソプロピルアルコール イソプロ 70 消プロ 70		皮膚 手術部位の皮膚 注射剤のアンブル・バイアル ドアノブ、水道ノブ 洋式トイレの便座 カート 医療器材		
アルコール系(中)	0.5%クロルヘキシジン含有の消毒用エタノール(通称:ヒビテンアルコール)	イワコールEエタノール オールガンエタノール クリゲンエタノール グルコキシジンアルコール グルコン酸クロルヘキシジンエタノール クロベインAエタノール クロヘキシジンアルコール ステリクロンエタノール フェルマジンアルコール ヘキサックアルコール ベンクロジドエタノール マスキエタノール ラポテックアルコール		手術部位の皮膚 医療器材		①粘膜や損傷皮膚には禁忌 ②首から上の術野消毒に用いない(誤って眼や耳へ入った場合、0.5%クロルヘキシジンおよび消毒用エタノールが毒性を示す) ③引火性に注意!(たとえば、術野消毒で患者と手術台の間にたまるほど大量に用いない)
	0.2%クロルヘキシジン含有の消毒用エタノール	ヒビソフト ヒビスコール アセスクリン ウエルアップ オールウエッシュ				
	0.2%塩化ベンザルコニウム含有の消毒用エタノール	ウエルバス ウエッシュクリーン ウエッシュクリーンゲル オスバンラビング カネバス ハンドコール ビオシラビング ベルコムローション ベンゼットラブ ホエスミンラビング ラビネット リナバス		手指<速乾性 手指消毒薬>		①傷や手荒れがある手指には用いない(刺激性がある) ②汚れのある手指では、流水下での手洗いおよび乾燥後に用いる(洗浄効果は期待できない) ③引火性に注意! ④綿球、ガーゼなどのセルロース類に吸着するので、有効濃度を下回らないように注意
	0.2%塩化ベンザルコニウム含有の 50%エタノール	トリゾンフォーム				
	0.5%ポビドンヨード含有の消毒用エタノール	イソジンバーム				

分類	一般名	商品名	使用濃度	消毒対象	備 考
ビグアナイド系 (低)	クロルヘキシジン	ヒビテン ヒビテングルコネート アビルテン オールカット クリゲン グルクロ グルコン酸クロル ヘキシジン クロキジーナ クロヘキシ クロルヘキシジン ステリクロン ネオクレミール フェルマジン ヘキザック ベンクロジド マスキ ラボテック	0.02%	外陰・外性器の 皮膚  結膜囊	①適用濃度に注意！ (たとえば、創部消毒に誤って0.5%を用いると、 ショックが生じる可能性がある)  ③外陰・外性器の皮膚や結膜囊への適用では、 無色のクロルヘキシジン（ヒビテングルコ ネートなど）を用いる  ③結膜囊への適用後には、滅菌水で洗い流す  ④膀胱・膣・耳へは禁忌
		<希釈済み製品> ヒビディール (0.05%)  ステリクロン W (0.02、0.05、0.1、0.5%)  ヘキザック水 W (0.02、0.05、0.1、0.5%)  マスキ水 (0.02、0.05、0.1、0.5%)  その他	0.05%	創傷部位	
			0.1～0.5%	手指  皮膚	
				医療器材	
		ヒビスクラブ マスキンスクラブ マイクロシールド	原液（4%）	手指	高度の頻回使用を避ける (手荒れの防止)
第四級アンモニウム塩 (低)	塩化ベンザルコニウム	オスバン エゾール 塩化ベンザルコニウム オロナイン-K カチノン	0.01%	感染皮膚面	
		カネトール 逆性石けん クレミール ザルコニン	0.01～0.025%	手術部位の粘膜  創傷部位	

分類	一般名	商品名	使用濃度	消毒対象	備考	
第四級 アンモ ニウム塩 (低)	塩化ベンザルコニウム	デアミトール ディタージサイド トリゾン ハイデシン パラステロール ピオシドール ホエスミン ヤクゾール	0.01 ~ 0.05%	結膜囊	①適用濃度に注意! (0.1%液は眼に, 5%液は皮膚に毒性を示す)  ②誤飲に注意! (誤飲されやすく, また経口毒性が高い)  ③結膜囊へ適用後には, 滅菌水で洗い流す	
		<希釈済み製品> オスバン液 (0.025、 0.05、0.1%)	0.02 ~ 0.05%	膺		
		ザルコニン液 (0.01、 0.025、0.05、0.1、2%)	0.1%	手指		
		デアミトール水 (0.025、0.05、0.1、 0.2%)				
		逆性石けん液「ヨシダ」 (0.01、0.02、0.025、 0.05、0.1%)	0.1 ~ 0.2%	医療器材 環境 (床など)		
	その他					
	8%エタノール含有の 0.1%塩化ベンザルコ ニウム	ザルコニン A 液 0.1	原液	気管内吸引チュ ーブ		
	塩化ベンゼトニウム	ハイアミン	0.01%	感染皮膚面		
		ハイアミンT	0.01 ~ 0.025%	手術部位の粘膜 創傷部位		
		<希釈済み製品> エンゼトニン液 (0.01、0.02、0.025、 0.05、0.1%)	0.02%	結膜囊		
		0.03%	膺			
		0.10%	手指			
ベゼトン液 (0.02、 0.025、0.05、0.1、 0.2%)		0.1 ~ 0.2%	医療器材 環境 (床など)			
ネオステリングリー ン歯科用液		0.004% (洗口)	口腔内			
	0.01 ~ 0.02%	拔牙創の感染 予防				

分類	一般名	商品名	使用濃度	消毒対象	備 考
両性界面活性剤 (低)	アルキルポリアミノ エチルグリシン	テゴー 51 アルキッド ウスノン エルエイジー キンサールG	0.01 ~ 0.05%	手術部位の粘膜 創傷部位	
		コンクノール サテニジン ニッサンアノン	0.05 ~ 0.2%	手指, 皮膚	
		ハイジール ハイパール パール ヒシバンチ ファスト-I  <希釈済み製品> エルエイジー液 (0.05, 0.1, 0.2, 0.5%)  サテニジン液 (0.05, 0.1, 0.2, 0.5%)	0.1 ~ 0.2%	医療器材  環境 (床など)	
色素系 (低)	アクリノール (リバノール)	アクリノール	0.05 ~ 0.1% (含嗽)	口腔領域における化膿局所	本薬での治療にもかかわらず原疾患の増悪がみられる場合には, 本薬による副作用 (潰瘍, 壊疽) を考慮する
		リバオール	0.05 ~ 0.2%	化膿局所	

濃度表示はアルコール系では v/v%, その他では w/v%。ただし, イソジンフィールドの項のエタノール濃度は w/v% で表示しており, v/v% に換算すると 63%。

## 病態別予防策のタイプおよび実施期間

### 1. 呼吸器系感染症

病 態	原因微生物	患者・状態	予防策	備 考
肺炎	アデノウイルス		飛沫、接触	罹病期間中
	ウイルス性、その他	成人 乳幼児	標準 接触	治療開始 24 時間
	A 群溶血性レンサ球菌	成人 乳幼児	標準 飛沫	治療開始 24 時間
	インフルエンザ杆菌	成人 乳幼児	標準 飛沫	治療開始 24 時間
	肺炎球菌 耐性 (PRSP、PISP)		標準 標準	
	黄色ブドウ球菌		標準	
	髄膜炎菌		飛沫	治療開始 24 時間
	レジオネラ		飛沫	治療開始 24 時間
	<i>Burkholderia cepacia</i>	膿嚢性肺線維症	標準	
	多剤耐性菌		接触	培養陰性となるまで
	その他の細菌性		標準	
	マイコプラズマ	異型肺炎	飛沫	罹病期間中
	クラミジア	オウム病	標準	
	真菌		標準	
	カリニ原虫		標準	
結核	肺結核 (確診・疑診、喉頭病変を含む)		空気	
	肺外、肺膿病変、髄膜炎、PPDs 陽性		標準	
百日咳	百日咳菌		飛沫	
細気管支炎		乳幼児	接触	罹病期間中
クループ		乳幼児	接触	罹病期間中
喉頭蓋炎	インフルエンザ杆菌		飛沫	治療開始 24 時間
呼吸器感染症	ウイルス性、急性	成人 乳幼児	標準 接触	罹病期間中
ヘルパンギーナ	腸管ウイルス		標準	
ヒストプラズマ症	ヒストプラズマ		標準	
ムコール症	ムコール		標準	
SARS	SARS コロナウイルス		飛沫	

## 2. 消化器系感染症

病 態	原因微生物	患者・状態	予防策	備 考
胃腸炎	カンピロバクター		標準	おむつ使用者（乳幼児を含む）および失禁状態の者は罹病期間中接触予防策
	コレラ			
	サルモネラ菌（チフス菌を含む）			
	赤痢菌			
	腸炎ビブリオ			
	腸管出血性大腸菌 O157:H7			
	ブドウ球菌			
	ロタウイルス			
	その他の細菌性、ウイルス性			
	クリプトスポリジウム			
	ジアルジア			
エルシニア・エンテロコリチカ				
赤痢	赤痢菌		標準	
	アメーバ			
腸チフス	チフス菌		標準	
食中毒	ボツリヌス中毒		標準	罹病期間中
	ウェルシュ菌			
	ブドウ球菌			
抗生物質関連腸炎	クロストリジウム・ディフィシル		接触	罹病期間中
壊死性腸炎			標準	
肝炎		通常	標準	
	A 型 (HAV)	おむつまたは失禁状態の者	接触	3 歳未満は入院期間中、3～14 歳は発症後 2 週間、15 歳以上は 1 週間
	B 型 (HBV) C 型 (HCV) 非 A 非 B E 型		標準	
胞虫症	エキノコッカス		標準	
便虫症			標準	

### 3. 全身性感染症、眼感染症、性感染症

病 態	原因微生物	患者・状態	予防策	備 考
エイズ	HIV		標準	
髄膜炎	髄膜炎菌 インフルエンザ杆菌		飛沫	治療開始後 24 時間
	肺炎球菌 結核菌 リステリア その他の細菌性、ウイルス性（無菌性） 真菌性		標準	
ライ症候群		乳幼児	標準	
ギラン-バレー症候群			標準	
リンパ球性脈絡髄膜炎			標準	
破傷風	破傷風菌		標準	
川崎病			標準	
リウマチ熱			標準	
ハンセン病			標準	
カンジダ症			標準	
トキシックショック症候群	ブドウ球菌		標準	
結膜炎	急性ウイルス性 急性細菌性 淋菌性 クラミジア性		接触 標準 標準 標準	罹病期間中
子宮内膜炎			標準	
尿路感染症		尿力テーテル有・無	標準	
梅毒		皮膚・粘膜、先天性・原発性、2 次性、潜在性・無症候性梅毒反応陽性者	標準	
淋病			標準	
鼠径リンパ肉腫			標準	
軟性下疳			標準	

## 4. 皮膚感染症、発疹

病 態	原因微生物	患者・状態	予防策	備 考
創感染		大 小	接触 標準	排膿がなくなるまで
褥瘡感染		大 小	接触 標準	排膿がなくなるまで
膿瘍		排膿多量 排膿少量	接触 標準	排膿がなくなるまで
膿痂疹			接触	治療開始後 24 時間
蜂巣炎		コントロール できない排膿	接触	排膿がなくなるまで
癬	ブドウ球菌	乳幼児	接触	罹病期間中
リッター病	ブドウ球菌性熱傷性皮膚症候群		標準	
閉鎖性感染症		排膿なし	標準	
野兔病	ツラレミア	排膿病変	標準	
カンジダ症		粘膜皮膚	標準	
疥癬			接触	治療開始後 24 時間
しらみ症			接触	治療開始後 24 時間
ライム病	スピロヘータ		標準	
ガス壊疽			標準	
水痘	VZV (水ぼうそう)		空気、接触	罹病期間中
带状疱疹	VZV	免疫不全者 播種性	空気、接触	罹病期間中
		健常者	標準	
麻疹	(はしか)		空気	罹病期間中
風疹	(三日ばしか)		飛沫	罹病期間中
先天性風疹		乳幼児	標準	1 歳まで
流行性耳下腺炎	Mumps (おたふくかぜ)		飛沫	腫脹出現から 9 日間
伝染性紅斑	パルボウイルス B19 (りんご病)	免疫不全者	飛沫	7 日間
		健常者	標準	
突発性発疹	HHS-6、7		標準	
手足口病	コクサッキー A16、10 エンテロウイルス 71 等		標準	
伝染性単核球症	EBV		標準	
伝染性軟属腫			標準	
ヘルパンギーナ	コクサッキー A3、4、5、6、8、10 等		標準	



## 5. 国際的感染症、輸入感染症

病 態	原因微生物	患者・状態	予防策	備 考
マラリア	マラリア原虫		標準	流行地では窓・扉に網
デング熱	デングウイルス		標準	流行地では窓・扉に網
ウイルス性出血熱	エボラ クリミア・コンゴ マールブルグ ラッサ		接触	罹病期間中
ウイルス熱	黄熱 コロラドダニ熱		標準	
ウイルス脳炎	東・西ベネズエラ脳炎 セントルイス脳炎 カリフォルニア脳炎		標準	
ブルセラ症	波状熱 マルタ熱 地中海熱		標準	
回帰熱	スピロヘータ		標準	
Q 熱	リケッチア		標準	

## 原因微生物別予防策のタイプおよび実施期間

	感染症	予防策	実施期間
あ	アクチノミセス	標準	罹病期間中
	アスペルギルス症	標準	
	アデノウイルス感染（乳幼児）	飛沫、接触	
	アメーバ症	標準	
	RS ウイルス感染症（乳幼児、免疫不全者）	接触	
い	EB ウイルス感染症（伝染性単核球症を含む）	標準	罹病期間中、陰圧室推奨
	インフルエンザ	飛沫	
え	エキノコックス	標準	罹病期間中 おむつまたは失禁患者は接触（3歳未満は入院期間中、3～14歳は発症後2週間まで、15歳以上は1週間）
	エコーウイルス（→腸管ウイルス）成人	標準	
	乳幼児	接触	
	HAV 感染症（A 型肝炎）	標準	
	HBV 感染症（B 型肝炎）	標準	
	HCV 感染症（C 型肝炎）	標準	
	HIV 感染症（AIDS）	標準	
	エボラ出血熱	接触	
	MRSA	接触	
	エルシニア・エンテロコリチカ	空気、接触	
	免疫不全者の胃腸炎、播種性 通常の患者の胃腸炎		
	エンテロウイルス感染症：成人	標準	
	乳幼児	接触	
か	回虫症	標準	
	カンジダ症（粘膜皮膚型を含む）	標準	
	カンピロバクター		
き	狂犬病	標準	
	ぎょう虫症	標準	
く	クラミジア・トラコマチス：結膜炎、性器、呼吸器	標準	罹病期間中
	クリプトコッカス症	標準	
	クリプトスポリジオーシス		
	クロイツフェルトーヤコブ病	標準	
	クロストリジウム：クロストリジウム・ディフィシル、 ボツリヌス菌、ウェルシュ菌、食中毒、ガス壊疽	接触、標準	

	感染症	予防策	実施期間
こ	抗酸菌：非結核性（異型）；肺、創部 鉤虫症 コクサッキーウイルス疾患（→エンテロウイルス感染症） コクシジオイデス症：排膿病変、肺炎 コレラ コロラドダニ熱	標準 標準 標準 標準	
さ	サイトメガロウイルス感染症： 新生児、免疫不全者 サルモネラ症	標準	
し	ジアルジア症（ランブル鞭毛虫） ジフテリア、喉頭炎 皮膚  住血吸虫症 出血熱（エボラ、ラッサなど） 条虫症（矮小条虫、有鉤条虫、その他） しらみ症	飛沫 接触  標準 接触 標準 接触	培養陰性、抗生物質中止に なるまで  罹病期間中  治療開始 24 時間まで
す	水痘 髄膜炎菌：敗血症、肺炎 スポロトリコーシス	空気、接触 飛沫 標準	曝露後 10～21 日 治療開始 24 時間まで
せ	接合菌症（ムコール菌症、藻菌症） 旋毛虫症	標準 標準	
た	带状疱疹（播種性） 大腸菌性胃腸炎 多剤耐性菌：感染症あるいは定着 胃腸炎、呼吸器、皮膚、創部、熱傷 呼吸器（肺炎球菌性）  たむし（皮膚真菌症、白癬） 炭疽病：皮膚、肺 単純ヘルペス：脳炎、粘膜皮膚、再発性（皮膚、口、性器） 新生児、粘膜皮膚、播種性、原発性、重症	空気、接触  標準 接触 標準  標準 標準 標準 接触	曝露後 10～21 日    培養陰性、抗生物質中止に なるまで  罹病期間中
ち	チフス、風土病および流行病性 腸炎ビブリオ 腸管ウイルス感染症：成人 乳幼児	標準  標準 接触	罹病期間中
て	デング熱	標準	流行地では窓・戸に網

	感染症	予防策	実施期間
と	トキソプラズマ症 トラコーマ、急性 トリコモナス症	標準 標準 標準	
の	ノカルジア症、排膿病変あるいは他の症状 ノロウイルス感染症	標準 接触、飛沫	
は	パラインフルエンザウイルス感染症、乳幼児 パルボウイルス B19  バンコマイシン耐性腸球菌 (VRE) ハンタウイルス呼吸器症候群	接触 飛沫  接触 標準	罹病期間中 免疫不全者には入院期間中、 無骨髄発作では 7 日間
ひ	ヒストプラズマ症 百日咳	標準 飛沫	治療開始から 5 日間
ふ	ブドウ球菌症：皮膚、創傷・熱傷：大 小  熱傷皮膚症候群 トキシック・ショック症候群  腸炎 肺炎	接触 標準 接触 標準 標準 標準	罹病期間中  罹病期間中  おむつ、失禁患者は接触
へ	ペスト：腺ペスト 肺ペスト ヘリコバクター・ピロリ	標準 飛沫 標準	治療開始 24 時間まで
ほ	ボツリヌス中毒 ポリオ	標準 標準	
ま	マイコプラズマ肺炎 麻疹	飛沫 空気	罹病期間中 罹病期間中
む	ムコール症 ムンプス	標準 飛沫	腫脹出現から 9 日間
め	メチシリン耐性黄色ブドウ球菌	接触	
よ	溶血性レンサ球菌感染症： A 群、乳幼児咽頭炎、肺炎 A 群、しょう紅熱 A 群、皮膚、創傷・熱傷：大 小 A 群、子宮内膜炎(産褥敗血症) 溶血性レンサ球菌感染症：B 群、新生児 溶血性レンサ球菌感染症 (その他)	飛沫  飛沫 接触 標準 標準 標準 標準	治療開始 24 時間まで 治療開始 24 時間まで 治療開始 24 時間まで
ら	ラッサ熱 ランブル鞭毛虫症	接触 標準	罹病期間中
り	リケッチア熱、ダニ (発疹チフス、ロッキー山紅斑熱)、 リケッチア痘症 (vesicular rickettsiosis)	標準 標準	

	感染症	予防策	実施期間
り	リステリア症 淋菌性新生児結膜炎（淋菌性眼炎）	標準 標準	
る	類鼻疽（すべての型）	標準	
れ	レジオネラ病 レプトスピラ	標準 標準	
ろ	ロタウイルス感染症（→胃腸炎） 失禁状態、おむつ（乳幼児、老人含む） ロッキー山紅斑熱	標準 接触 標準	罹病期間中

#### 参考文献

- 1) American Thoracic Society, CDC, and Infectious Diseases Society of America: Treatment of Tuberculosis, MMWR, 52 (RR-11): 1-77, 2003.
- 2) CDC and Healthcare Infection Control Practices Advisory Committee: Guidelines for Environmental Infection Control in Health-Care Facilities, MMWR, 52 (RR-10): 1-42, 2003.
- 3) Health-Care Infection Control Practices Advisory Committee/ SHEA/APIC/IDSA Hand Hygiene Task Force: Guideline for Hand Hygiene in Health-Care Settings, MMWR, 51 (RR-16): 1-, 2002.
- 4) Guidelines for the Prevention of Intravascular Catheter-Related Infections, MMWR, 51 (RR-10), 2002.
- 5) Hospital Infection Control Practices Advisory Committee: Isolation Guideline. Part I. Evolution of Isolation Practices, DHQP Issues in Healthcare Settings 1994, p.1-9.
- 6) ICU 感染制御 CPG 策定委員会（国立大学集中治療部協議会）: ICU 感染対策 Clinical Practice Guideline, 2003.
- 7) 感染症の診断・治療研究会: 感染症の診断・治療ガイドライン, 日本医師会雑誌, 122 (10), 1999.
- 8) 東京都新たな感染症対策委員会: 東京都感染症マニュアル, 2001.
- 9) 小林寛伊: 消毒, 滅菌ガイド, 中外医学社, 1998.
- 10) 小林寛伊, 吉倉廣, 荒川宜親編: エビデンスに基づいた感染制御, 第1集 基礎編, 改訂2版, メヂカルフレンド社, 2003.
- 11) 小林寛伊, 吉倉廣, 荒川宜親, 倉辻忠俊編: エビデンスに基づいた感染制御, 第2集 実践編, メヂカルフレンド社, 2003.
- 12) 小林寛伊, 吉倉廣, 荒川宜親, 倉辻忠俊編: エビデンスに基づいた感染制御, 第3集 展開編, メヂカルフレンド社, 2003.
- 13) WHO/CDS/CSR/APH: WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. Report of a WHO consultation, 1999, p.1-38.
- 14) 厚生労働省遅発性ウイルス感染症調査研究班: クロイツフェルト・ヤコブ病診療マニュアル, 改訂版, 2002, p.1-49.

## AAC(6′)-Iaf, a Novel Aminoglycoside 6′-N-Acetyltransferase from Multidrug-Resistant *Pseudomonas aeruginosa* Clinical Isolates<sup>†</sup>

Tomoe Kitao, Tohru Miyoshi-Akiyama, and Teruo Kirikae\*

Department of Infectious Diseases, Research Institute, International Medical Center of Japan, Shinjuku, Tokyo 162-8655, Japan

Received 9 October 2008/Returned for modification 20 November 2008/Accepted 29 March 2009

We report here the characterization of a novel aminoglycoside resistance gene, *aac(6′)-Iaf*, present in two multidrug-resistant (MDR) *Pseudomonas aeruginosa* clinical isolates. These isolates, IMCJ798 and IMCJ799, were independently obtained from two patients, one with a urinary tract infection and the other with a decubitus ulcer, in a hospital located in the western part of Japan. Although the antibiotic resistance profiles of IMCJ798 and IMCJ799 were similar to that of MDR *P. aeruginosa* IMCJ2.S1, which caused outbreaks in the eastern part of Japan, the pulsed-field gel electrophoresis patterns for these isolates were different from that for IMCJ2.S1. Both IMCJ798 and IMCJ799 were found to contain a novel chromosomal class 1 integron, In123, which included *aac(6′)-Iaf* as the first cassette gene. The encoded protein, AAC(6′)-Iaf, was found to consist of 183 amino acids, with 91 and 87% identity to AAC(6′)-Iq and AAC(6′)-Im, respectively. IMCJ798, IMCJ799, and *Escherichia coli* transformants carrying a plasmid containing the *aac(6′)-Iaf* gene and its upstream region were highly resistant to amikacin, dibekacin, and kanamycin but not to gentamicin. The production of AAC(6′)-Iaf in these strains was confirmed by Western blot analysis. Thin-layer chromatography indicated that AAC(6′)-Iaf is a functional acetyltransferase that specifically modifies the amino groups at the 6′ positions of aminoglycosides. Collectively, these findings indicate that AAC(6′)-Iaf contributes to aminoglycoside resistance.

*Pseudomonas aeruginosa* is a nosocomial pathogen that exhibits a remarkable ability to acquire resistance to several antibiotics. The most serious problem has been the emergence of multidrug-resistant (MDR) *P. aeruginosa* strains with resistance to all  $\beta$ -lactams, aminoglycosides, and quinolones (39, 40). In Japan, MDR *P. aeruginosa* is defined as having resistance to carbapenem (MIC  $\geq$  16  $\mu$ g/ml), amikacin (AMK; MIC  $\geq$  32  $\mu$ g/ml), and fluoroquinolone (MIC  $\geq$  4  $\mu$ g/ml).

Bacterial resistance to aminoglycosides can result from three causes (44): decreased membrane permeability (13), the modification of 16S RNA (14, 16, 17, 49) or ribosomal proteins (13), and the enzymatic modification of aminoglycosides. In *P. aeruginosa* isolates, resistance to aminoglycosides is due primarily to the production of aminoglycoside-modifying enzymes (4, 47). The aminoglycoside acetyltransferases (AACs) are aminoglycoside-modifying enzymes that transfer acetyl groups to the amino groups of aminoglycosides. The AACs can be grouped into four classes, AAC(1), AAC(2′), AAC(3′), and AAC(6′), based on the acetylation sites of the aminoglycosides (22, 44). N-acetylation at the 6′ position catalyzed by AAC(6′) is one of the most prevalent forms of modification of aminoglycosides (32). AAC(6′)-I confers resistance to AMK but not to gentamicin (GEM) (41). To date, at least 27 AAC(6′)-I enzymes, designated AAC(6′)-Ia to AAC(6′)-Iae, have been identified and characterized (15, 22, 38, 44). In contrast, only two AAC(6′)-II enzymes, which confer resistance to GEM but not to AMK, have been identified (41). The *aac* genes are

often found in class 1 integrons (21). These integrons possess two conserved segments at each end, separated by a variable region that includes integrated antibiotic resistance gene cassettes (19, 20). The 5′-conserved segment (5′-CS) contains the *intI* gene, and the 3′-conserved segment (3′-CS) contains the *qacEΔI* and *sulI* genes (19).

We previously described a nosocomial outbreak of catheter-associated urinary tract infection with an MDR *P. aeruginosa* strain, IMCJ2.S1, in a hospital in the Tohoku region in the eastern part of Japan (39). IMCJ2.S1 was found to harbor an aminoglycoside 6′-N-acetyltransferase gene, *aac(6′)-Iae*, in a chromosomal integron. We developed kits to detect the *aac(6′)-Iae* gene and the AAC(6′)-Iae protein and used these kits to survey MDR *P. aeruginosa* strains in hospitals throughout Japan (27, 39). During surveillance in the western part of Japan, two MDR *P. aeruginosa* clinical isolates negative for *aac(6′)-Iae* were identified. Each of these isolates contained a novel aminoglycoside 6′-N-acetyltransferase gene, *aac(6′)-Iaf*. We report here the structure of this gene and the properties of its product.

### MATERIALS AND METHODS

**Bacterial strains and plasmids.** Two *P. aeruginosa* clinical isolates, IMCJ798 and IMCJ799, were individually obtained from two patients, one with a urinary tract infection and the other with a decubitus ulcer. *P. aeruginosa* ATCC 27853 was obtained from the American Type Culture Collection (Manassas, VA) and used as a reference strain for antibiotic susceptibility testing. *Escherichia coli* strains DH5 $\alpha$  (Takara Bio, Shiga, Japan) and JM109 (Stratagene, La Jolla, CA) were used as hosts for recombinant plasmids. *E. coli* BL21(DE3)(pLysS) (Invitrogen, Carlsbad, CA) was used for the expression of recombinant *aac(6′)-Iaf*. A rifampin-resistant mutant of *P. aeruginosa*, ATCC 27853 Rfp<sup>r</sup>, was used for conjugation. *P. aeruginosa* GN17203, carrying plasmid pMS350 containing *bla*<sub>IMP-1</sub> (46), was kindly provided by S. Iyobe (Kitasato University, Sagami-hara, Japan).

\* Corresponding author. Mailing address: Department of Infectious Diseases, Research Institute, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku, Tokyo 162-8655, Japan. Phone: (81) 3 3202 7181, ext. 2838. Fax: (81) 3 3202 7364. E-mail: tkirikae@ri.imcj.go.jp.

<sup>†</sup> Published ahead of print on 6 April 2009.

TABLE 1. PCR primers used in this study

Primer	Sequence <sup>a</sup> (5' to 3')	Label in Fig. 2	Description	Reference
5'-CS	GGCATCCAAGCAGCAAG	B	5'-End common segment of class 1 integrons	29
3'-CS	AAGCAGACTTGACCTGA	F	3'-End common segment of class 1 integrons	29
intI-R	TGCGTGTAATCATCGTCGT	A	Positions 196–177 in <i>intI1</i>	38
qacEdelta-R	GCAATTATGAGCCCCATACC	G	Positions 287–268 in <i>qacEΔ1</i>	38
sulI-R	GGGTTCGAGAAAGGTGATT	H	Positions 787–768 in <i>sulI</i>	38
aac(6')Iaf-F	TTGGACTATTCAATATGCCA	C	Positions 1–20 in <i>aac(6')-Iaf</i>	This study
aac(6')Iaf-R	CTAGCTAATATCTTTCCACA	D	Positions 552–533 in <i>aac(6')-Iaf</i>	This study
blaIMP-1-F	GAAGTTAACCGGTGGGGCG		Positions 124–142 in <i>bla<sub>IMP-1</sub></i>	This study
blaIMP-1-R	CTTTAACCGCTGCTCTAAT	E	Positions 700–681 in <i>bla<sub>IMP-1</sub></i>	This study
16S-rRNA-F	ATGCAAGTCGAGCGGATGAAGGGAG		Positions 55–79 in 16S rRNA gene	This study
16S-rRNA-R	TAGTCGACATCGTTTACGGCGTGGA		Positions 822–798 in 16S rRNA gene	This study
23S-rRNA-F	CGAGGACAGTGTATGGTGGGCAGT		Positions 2207–2231 in 23S rRNA gene	This study
23S-rRNA-R	CTCAACGCCTCACAAACGCTTACACA		Positions 2856–2832 in 23S rRNA gene	This study
PstI-aac-F	aactgcagGGCTTGTATGACTGTTTTT		Sequence in the 185- to 166-bp upstream region of <i>aac(6')-Iaf</i> with PstI site	This study
EcoRI-aac-R	ggaattcCTAGCTAATATCTTTCCACA		Positions 552–533 in <i>aac(6')-Iaf</i> with EcoRI site	This study
SphI-aac-F	aaagcatgCGATGGACTATTCAATATGCCA		Positions 1–20 in <i>aac(6')-Iaf</i> with SphI <sup>b</sup> site	This study
PstI-aac-R	aactgcagCTAGCTAATATCTTTCCACA		Positions 552–533 in <i>aac(6')-Iaf</i> with PstI site	This study

<sup>a</sup> Lowercase letters represent restriction enzyme recognition sites attached on the 5' ends of primers.

<sup>b</sup> The initiation codon TTG in *aac(6')-Iaf* was replaced with ATG.

**Antimicrobial agents.** Amikacin (AMK) and imipenem (IPM) were obtained from Banyu Pharmaceutical Co. (Tokyo, Japan), arbekacin (ABK) and dibekacin (DIB) were purchased from Meiji Seika Kaisha, Ltd. (Tokyo, Japan), aztreonam (ATM) was obtained from Eisai (Tokyo, Japan), ceftazidime (CAZ) was acquired from GlaxoSmithKline K.K. (Tokyo, Japan), gentamicin (GEM) and neomycin B and C mixtures (NEO) were obtained from Nacalai Tesque, Inc. (Kyoto, Japan), isepamicin (ISP), netilmicin (NET), and sisomicin (SIS) were from Schering-Plough K.K. (Osaka, Japan), kanamycin A (KAN) and polymyxin B (PMB) were purchased from Sigma-Aldrich (St. Louis, MO), meropenem (MEM) was obtained from Sumitomo Pharmaceutical Co., Ltd. (Osaka, Japan), ofloxacin (OFX) was acquired from Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan), piperacillin (PIP) and piperacillin-tazobactam (TZP) were obtained from Tomiyama Pure Chemical Industries, Ltd. (Tokyo, Japan), and tobramycin (TOB) was purchased from Towa Pharmaceutical Co., Ltd. (Osaka, Japan).

**In vitro susceptibility tests.** MICs were determined using a microdilution method according to the protocols recommended by the Clinical and Laboratory Standards Institute (10).

**Serotyping.** The O serotypes of isolates were determined with a slide agglutination test kit (Denka Seiken Co., Tokyo, Japan).

**Detection of MDR *P. aeruginosa* using a LAMP method and an agglutination test.** The *aac(6')-Iae* gene was assessed using a loop-mediated isothermal amplification (LAMP) method, and the AAC(6')-Iae protein was evaluated using an agglutination test, as described previously (39).

**PFGE.** DNA plugs were prepared as described previously (18) and digested overnight at 37°C with SpeI and XbaI (Takara Bio). Pulsed-field gel electrophoresis (PFGE) analysis was performed as described previously (38).

**PCR amplification of class 1 integrons.** Genomic DNA was extracted as described previously (36) and used as PCR templates. Class 1 integrons were detected by PCR using 5'-CS and 3'-CS primers as described previously (11, 29) and genetically mapped using the primers listed in Table 1. An Expand high-fidelity PCR system (Roche Diagnostics GmbH, Penzberg, Germany) was used for all PCR amplifications. All PCR products were sequenced to identify genes and their orders in the integrons.

**DNA sequencing.** DNA sequences were determined using an ABI PRISM 3100 sequencer (Applied Biosystems). Homology searches of nucleotide and translated protein sequences were performed using BLAST (2, 3). Multiple-sequence alignments and searches for open reading frames (ORFs) were performed using the Clustal W2 program (28) and GENETYX software (Genetyx, Tokyo, Japan). The dendrogram for AACs was determined with the Clustal W2 program (28).

**Plasmid extraction.** The methods of Kado and Liu (25) and Casse et al. (8), modified as follows, were used to extract plasmid DNA from *P. aeruginosa*. The bacterial pellet was lysed by the addition of 2 ml of lysis buffer (50 mM Tris-Cl, 20 mM EDTA, 4% sodium dodecyl sulfate [SDS], pH 12.6), followed by gentle shaking for 30 min at 37°C. The lvsate was neutralized by adding 400 μl of 1 M

Tris-Cl (pH 7.5), and the proteins were precipitated by adding 250 μl of 5 M NaCl. The solution was extracted with an equal volume of phenol-chloroform solution (1:1, vol/vol). The plasmid DNA in the aqueous phase was precipitated by adding a twofold volume of 100% ethanol. The DNA pellet was collected. Plasmid DNA preparations were analyzed by electrophoresis on 0.7% agarose gels in 0.5× Tris-borate-EDTA buffer at 4°C.

**Transformation using plasmid preparations from *P. aeruginosa* IMCJ798 and IMCJ799.** Plasmid preparations from *P. aeruginosa* strains were used to transform *E. coli* DH5α and *P. aeruginosa* PAO1 by electroporation using a Gene Pulser Xcell system (Bio-Rad Laboratories, Hercules, CA). The transformants were cultured on Luria-Bertani (LB) agar plates containing 20 μg/ml AMK for 24 h at 37°C.

**Transfer of aminoglycoside resistance.** Drug resistance was transferred from *P. aeruginosa* clinical isolates to a rifampin-resistant mutant of *P. aeruginosa*, ATCC 27853 Rfp<sup>r</sup>, using the broth mating method (26). The transconjugants were selected on Mueller-Hinton agar plates containing rifampin (200 μg/ml) and IPM (16 μg/ml) or AMK (20 μg/ml).

**Genome typing by I-CeuI digestion and Southern blot hybridization.** DNA plugs containing total genomic DNA from isolates were digested overnight with I-CeuI. DNA fragments were separated by PFGE. Southern hybridization was performed using an enhanced chemiluminescence direct nucleic acid-labeling and detection system according to the instructions of the manufacturer (GE Healthcare, Tokyo, Japan), as described previously (24, 30, 34), to determine whether the novel class 1 integron identified in the *P. aeruginosa* isolates, designated In123, has a chromosomal location. Probes for *aac(6')-Iaf*, *bla<sub>IMP-1</sub>*, 16S rRNA, and 23S rRNA genes from IMCJ798 were amplified by PCR using the primer sets *aac(6')Iaf-F/aac(6')Iaf-R*, *blaIMP-1-F/blaIMP-1-R*, *16S-rRNA-F/16S-rRNA-R*, and *23S-rRNA-F/23S-rRNA-R*, respectively (Table 1).

**Cloning of *aac(6')-Iaf* gene.** The ORF of *aac(6')-Iaf* and 185 bp of the upstream region of the gene, which includes the promoter, were PCR amplified from *P. aeruginosa* IMCJ798 by using the primer set PstI-aac-F and EcoRI-aac-R (Table 1). The PCR products were digested with EcoRI and PstI and ligated into the PstI and EcoRI sites of pSTV28, at a polarity opposite the transcriptional direction of the promoter on the vector. The plasmids were used to transform DH5α, and transformants were selected on LB agar containing 30 μg/ml of chloramphenicol. The resulting plasmid was designated pSTV-aacWT. To determine MICs, *E. coli* JM109 was transformed with pSTV-aacWT, which represses transcription driven by the promoter on the pSTV28 vector.

**Site-directed mutagenesis.** The putative initiation codon on pSTV-aacWT, TTG, was replaced by ATG by using a QuikChange site-directed mutagenesis kit (Stratagene). The resulting plasmid was designated pSTV-aac(TTG→ATG). To determine MICs, *E. coli* JM109 was transformed with this plasmid.

**Construction of AAC(6')-Iaf-overexpressing strains.** The *aac(6')-Iaf* gene from *P. aeruginosa* IMCJ798 was PCR amplified using the primer set SphI-aac-F and PstI-aac-R (Table 1), and the product was digested with SphI and PstI and

TABLE 2. Antimicrobial susceptibility parameters of IMCJ798, IMCJ799, IMCJ2.S1, and ATCC 27853 for various antibiotics<sup>a</sup>

Isolate name	MIC ( $\mu\text{g/ml}$ ) of:										
	PIP	TZP	CAZ	IPM	MEM	ATM	AMK	ABK	GEM	OFX	PMB
IMCJ798	256	256	512	128	>512	64	128	8	4	>128	4
IMCJ799	256	256	512	128	>512	64	128	16	2	>128	4
IMCJ2.S1	256	256	512	128	512	128	128	2	16	128	2
ATCC 27853	<4	4	<1	4	1	2	2	<0.5	<1	<0.5	2

<sup>a</sup> PIP, piperacillin; TZP, piperacillin-tazobactam; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; ATM, aztreonam; AMK, amikacin; ABK, arbekacin; GEM, gentamicin; OFX, ofloxacin; PMB, polymyxin B.

ligated into pQE2 (Invitrogen), which had been digested with the same restriction enzymes. The plasmid was used to transform DH5 $\alpha$ , and the transformants were selected on LB agar containing 100  $\mu\text{g/ml}$  of ampicillin. The resulting plasmid, pQE-*aac(6')-Iaf*, was used to transform *E. coli* BL21(DE3)(pLys), which was used for recombinant protein purification.

**Purification of recombinant AAC(6')-Iaf.** *E. coli* BL21(DE3)(pLys) carrying plasmid pQE2-*aac(6')-Iaf* was grown in LB medium containing 200  $\mu\text{g/ml}$  ampicillin at 37°C until the  $A_{600}$  reached 0.3. IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside) was added to a concentration of 0.1 mM to induce the expression of AAC(6')-Iaf, and the culture was incubated for 4 h at 37°C. The hexahistidine-tagged AAC(6')-Iaf was purified from the soluble fraction using Ni-nitrilotriacetic acid agarose according to the instructions of the manufacturer (Qiagen, Tokyo, Japan). The final concentration of protein was determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL).

**Purification of native AAC(6')-Iaf from *P. aeruginosa*.** Rabbits were immunized with recombinant AAC(6')-Iaf protein emulsified in Freund's adjuvant. The animal experiments were approved by the ethical committee for animal experiments at the Research Institute of the International Medical Center of Japan. Anti-AAC(6')-Iaf immunoglobulin G (IgG), purified from the rabbit sera on protein G-Sepharose (GE Healthcare), was coupled to NHS-activated Sepharose according to the instructions of the manufacturer (GE Healthcare). Bacterial cells from overnight cultures of *P. aeruginosa* IMCJ798 were disrupted by sonication, and the cleared lysate was applied to the IgG-coupled Sepharose column. After the column was washed with phosphate-buffered saline containing 0.05% Tween 20, protein was eluted with 0.1 M glycine-HCl (pH 2.5). The purified protein was dialyzed in Tris-buffered saline (50 mM Tris, 150 mM NaCl, pH 8.0) and separated by SDS-15% polyacrylamide gel electrophoresis (SDS-15% PAGE), and the N-terminal sequence was analyzed by a commercial service (Nippi, Inc., Tokyo, Japan).

**Western blotting.** *E. coli* JM109 bacteria carrying pSTV28, pSTV-*aacWT*, or pSTV-*aac(TTG→ATG)* were cultivated for 16 h at 37°C in LB broth containing 30  $\mu\text{g/ml}$  chloramphenicol. *P. aeruginosa* isolates IMCJ798 and IMCJ799 were cultivated for 16 h at 37°C in LB broth containing 20  $\mu\text{g/ml}$  AMK. One milliliter of each culture was collected by centrifugation, and whole-cell lysates in 200  $\mu\text{l}$  of SDS-PAGE sample buffer were prepared. A 5- $\mu\text{l}$  aliquot of each cell lysate was separated on an SDS-15% PAGE gel, and the proteins were transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% skim milk in a mixture of 20 mM Tris (pH 8.0), 150 mM NaCl, and 0.05% Tween 20 and incubated with rabbit polyclonal anti-AAC(6')-Iaf antibodies, obtained by immunization with His-AAC(6')-Iaf. After the incubation of the membranes with secondary horseradish peroxidase-linked anti-rabbit IgG (GE Healthcare), bands were detected by chemiluminescence. The intensity of each band was quantified using Quantity One software (Bio-Rad Laboratories).

**TLC analysis of acetylated aminoglycosides.** Mixtures containing 2 mM aminoglycoside, 2 mM acetyl coenzyme A (acetyl-CoA), and 50  $\mu\text{g/ml}$  AAC(6')-Iaf in 20  $\mu\text{l}$  of phosphate buffer (pH 7.4) were incubated for 16 h at 37°C, 3  $\mu\text{l}$  of each aminoglycoside mixture was spotted onto the surface of a silica gel 60 thin-layer chromatography (TLC) plate containing a fluorescence indicator with a 254-nm excitation wavelength (Merck Ltd., Japan), and the results were developed with 5% phosphate potassium solution. The aminoglycosides and their acetylated products were detected with 0.5% ninhydrin in acetone (50).

**Nucleotide sequence accession number.** The nucleotide sequence of In123 determined in this study has been deposited in the EMBL and GenBank databases and the DDBJ and assigned accession number AB462903.

## RESULTS AND DISCUSSION

### Characterization of *P. aeruginosa* IMCJ798 and IMCJ799.

We obtained two *P. aeruginosa* clinical isolates, IMCJ798 and IMCJ799, from two patients, one with a urinary tract infection and the other with a decubitus ulcer, from a hospital in the Chugoku region of western Japan in 2007. After the implementation of various infection control measures, no other patients with such infections were detected.

The genotypic and phenotypic properties of IMCJ798 and IMCJ799 were compared with those of the MDR *P. aeruginosa* strain IMCJ2.S1, which had been reported previously to be found in Japan (38). The MICs for *P. aeruginosa* IMCJ798, IMCJ799, IMCJ2.S1, and ATCC 27853 are shown in Table 2. Multidrug resistance phenotypes were observed in IMCJ798 and IMCJ799. These isolates were resistant to all antibiotics except for GEM. In particular, they showed high levels of resistance to  $\beta$ -lactams, AMK, and OFX. These results were similar to those for IMCJ2.S1, except for ABK and GEM (Table 2). IMCJ798, IMCJ799, and IMCJ2.S1 also had the same serotype, O:11. Although IMCJ798 and IMCJ799 seemed to be derived from IMCJ2.S1, both were negative for the *aac(6')-Iae* gene by the LAMP method (data not shown) and for AAC(6')-Iae protein by the agglutination test (data not shown), whereas IMCJ2.S1 was positive for *aac(6')-Iae* (39). The PFGE patterns of SpeI- and XbaI-digested fragments from the IMCJ798 and IMCJ799 isolates were identical but differed from those of fragments from IMCJ2.S1 (Fig. 1). The PFGE patterns for IMCJ798 and IMCJ799 showed similarities of 56.4% (SpeI) and 70.5% (XbaI), respectively, to that for IMCJ2.S1. Thus, the genotypic properties of IMCJ798 and IMCJ799 differed from those of IMCJ2.S1, although these strains had similar phenotypes. Further nationwide, hospital-based surveillance of MDR *P. aeruginosa* is required.

***aac(6')-Iaf* in the class 1 integron.** To identify the drug resistance genes of IMCJ798 and IMCJ799, the variable regions of class 1 integrons were amplified with primers 5'-CS and 3'-CS (Table 1). Amplicons of 1.7 kbp generated from both strains were found to be identical by DNA sequencing. Sequence analysis revealed a variable region containing two cassettes, one carrying a novel *aac(6')* gene and the other carrying a *bla*<sub>IMP-1</sub> metallo- $\beta$ -lactamase gene (Fig. 2). The novel *aac(6')* gene comprised an ORF of 552 bp, starting with a TTG codon, and its sequence showed 94 and 91% identity to those of *aac(6')-Iq* from *Klebsiella pneumoniae* (9) and *aac(6')-Im* from *Citrobacter freundii* (23). Based on the standard nomenclature (45), we named this ORF *aac(6')-Iaf*.






FIG. 1. PFGE patterns for *SpeI*- and *XbaI*-digested genomic DNA from MDR *P. aeruginosa* strains IMCJ798 and IMCJ799. The DNA fragments were detected by ethidium bromide staining. Results for IMCJ798 (lanes 1), IMCJ799 (lanes 2), and IMCJ2.S1 (lanes 3) are shown.

The 5' CS and 3' CS of the integron were further mapped with PCR cartography using external primers (Table 1; Fig. 2). Typical 59-base elements (42) were observed in both cassettes. These results supported the idea that the *aac(6')-Iaf* gene in *P. aeruginosa* IMCJ798 and IMCJ799 is localized within the class 1 integron. The sequence of the integron was not found in any database; we therefore named the integron In123.

In addition, the *aac(6')-Iaf* gene has a G+C content of 34.4%; in contrast, the average G+C contents of the *P. aeruginosa* PAO1 and *K. pneumoniae* MGH78578 genomes are 66.6 and 57.1%, respectively (<http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi?view=1>). These findings suggested that *aac(6')-Iaf* may be derived from species with intrinsically low G+C contents, not from *Pseudomonas* or *Klebsiella* species.

**Location of In123.** Class 1 integrons are frequently located on plasmids, and they can be transferred among bacteria (5). Plasmid preparation, transformation, conjugation, and Southern hybridization using genomic DNA digested by *I-CeuI* were carried out to determine the locations and transmission ability of In123 in IMCJ798 and IMCJ799. *P. aeruginosa* GN17203, which harbors pMS350 containing *bla<sub>IMP-1</sub>*, was used as the positive control (46). Initially, we prepared plasmid DNA as described in Materials and Methods. No plasmid in IMCJ798 or IMCJ799 was detected by electrophoresis, whereas pMS350 was detected in *P. aeruginosa* GN17203 (data not shown). *E. coli* DH5 $\alpha$  and *P. aeruginosa* PAO1 were transformed with the plasmid DNA preparations by electroporation. No transformants were obtained on LB agar plates containing AMK. In conjugation tests using *P. aeruginosa* ATCC 27853 Rfp<sup>r</sup> as a recipient strain, the AMK resistance was not transferred from




FIG. 2. Genetic structure of In123. Primers labeled A, B, C, D, E, F, G, and H are described in Table 1. Arrows indicate primer locations and directions.




FIG. 3. PFGE patterns (A and C) and Southern hybridization analyses (B and D) of *P. aeruginosa* genomic DNA digested by *I-CeuI*. PFGE analysis of *P. aeruginosa* genomic DNA digested with *I-CeuI* was done under the following two different sets of conditions: condition set 1 for the separation of the largest, 4.0-Mb fragment of PAO1 (A) consisted of a 106° angle, 0.8% agarose, and linear switching times of 20 to 30 min for 48 h with a voltage gradient of 2 V/cm, and condition set 2 for the separation of the 950-, 775-, and 475-kb fragments of PAO1 (C) consisted of a 120° angle, 1% agarose, and nonlinear switching times of 5.3 to 120 s for 19.5 h with a voltage gradient of 6 V/cm. The molecular standards were *Schizosaccharomyces pombe* (A) and *Saccharomyces cerevisiae* YPH80 (C). An arrow in panel C indicates the location of an extrachromosomal band that may correspond to pMS350. DNA fragments for which results are shown in panels A and C were transferred onto membranes and were used for the hybridization analyses presented in panels B and D, respectively. Southern hybridization was performed with probes for rRNA genes, *aac(6')-Iaf*, and *bla<sub>IMP-1</sub>*, as shown in panels B and D. EtBr, ethidium bromide.

IMCJ798 and IMCJ799 to *P. aeruginosa* ATCC 27853 Rfp<sup>r</sup> whereas carbapenem resistance was transferred from *P. aeruginosa* GN17203 to ATCC 27853 Rfp<sup>r</sup>. In order to confirm that In123 is located on the chromosome, PFGE analysis and Southern hybridizations using *P. aeruginosa* genomic DNA digested by *I-CeuI* were performed. In all strains, four chromosomal fragments of various sizes (PAO1, 4,063, 950, 775, and 475 kb; GN17203, ca. 3,600, 1,500, 945, and 900 kb; and IMCJ798 and IMCJ799, ca. 4,500, 950, 900, and 480 kb) were detected by the rRNA gene probes (Fig. 3A and C and left panels in B and D). The *aac(6')-Iaf* probe detected the 4,500-kb fragments from IMCJ798 and IMCJ799. The band hybridized by the *aac(6')-Iaf* probe was also recognized by the rRNA gene probe. The *bla<sub>IMP-1</sub>* probe detected the same fragments in the IMCJ798 and IMCJ799 clinical isolates as the *aac(6')-Iaf* and rRNA gene probes. Additionally, the *bla<sub>IMP-1</sub>* probe detected a 700-kbp extrachromosomal fragment, which may correspond to pMS350 in GN17203 (46), that was not




FIG. 4. Phylogenetic tree and amino acid sequence alignments for the AAC(6')-I subfamily. (A) Phylogenetic relationships were determined with the Clustal W2 program. aa, amino acids. (B) Dots indicate amino acids identical to those of AAC(6')-Iaf. Black-highlighted amino acids are conserved among this AAC(6')-I subfamily. Dashes represent gaps introduced to optimize similarity.

detected by the rRNA gene probe. Another smaller *bla*<sub>IMP-1</sub> probe-specific band detected in the IMCJ798 and IMCJ799 clinical isolates, as shown in Fig. 3B, was not observed in the analysis presented in Fig. 3D, probably due to differences in electrophoretic conditions (see the legend to Fig. 3). It is likely that this band was not resolved under the conditions used in the analyses presented in Fig. 3C and D.

Collectively, these results strongly suggest that In123, which carries *aac(6')-Iaf*, is located on a chromosome, not on a plasmid, in *P. aeruginosa* IMCJ798 and IMCJ799. This arrangement is similar to those for other class 1 integrons, including *aac(3)-Ib*, *aac(3)-Ic*, and *aac(6')-Iae* integrons in *P. aeruginosa* (35, 37) and the *aac(3)-Id* integron in *Vibrio fluvialis* (1).

**Comparison of AAC(6')-Iaf with other AAC(6')-I enzymes.** AAC(6')-Iaf, encoded by the first cassette gene in In123, consists of 183 amino acids. The amino acid sequence of AAC(6')-Iaf was compared to those of other AAC(6')-I enzymes. The deduced molecular phylogeny of these sequences suggests that all the AAC(6')-I enzymes can be classified into three subfamilies (44), the first containing AAC(6')-Ib and AAC(6')-Ie, the second containing AAC(6')-Ic, AAC(6')-Id, and AAC(6')-Ih,

and the third containing AAC(6')-Ia, AAC(6')-Iae, and AAC(6')-Iq. It was found that AAC(6')-Iaf belonged to the third subfamily, whose members show considerable phylogenetic distance from those of the other two subfamilies, which include AAC(6')-Ib or AAC(6')-Iad (15, 38, 44). Using multiple-sequence alignments, AAC(6')-Iaf was found to have 91, 87, 63, 57, and 35% identity to AAC(6')-Iq from *K. pneumoniae* (9), AAC(6')-Im from *C. freundii* (23), AAC(6')-Ia from *Shigella sonnei* (43), AAC(6')-Iae from *P. aeruginosa* (38), and AAC(6')-Ii from *Enterococcus faecium* (12), respectively (Fig. 4A). Moreover, four motifs (C, D, A, and B) of GCN5-related N-acetyltransferases (33) were also observed in AAC(6')-Iaf, as well as most other AAC(6')-I enzymes (Fig. 4B). Additionally, the crystal structure of AAC(6')-Ii, which also belongs to the third subfamily, has been resolved, and two acetyl-CoA binding sites have been reported (6, 7). Putative sites required for acetyl-CoA binding, sites 1 and 2, were also found in AAC(6')-Iaf (Fig. 4B).

**Effects of *aac(6')-Iaf* on aminoglycoside resistance.** Both *P. aeruginosa* IMCJ798 and IMCJ799 were resistant to AMK, DIB, ISP, KAN, NET, and TOB but were sensitive to GEM

TABLE 3. MICs of various aminoglycosides for *P. aeruginosa* strains and *E. coli* strains transformed with *aac(6')-Iaf*

Strain <sup>a</sup>	MIC <sup>b</sup> (μg/ml) of:									
	AMK	ABK	DIB	GEM	ISP	KAN	NET	SIS	TOB	NEO
<i>P. aeruginosa</i> IMCJ798	128	8	>128	4	>128	>128	>128	32	32	8
<i>P. aeruginosa</i> IMCJ799	128	16	>128	2	>128	>128	>128	32	32	8
<i>E. coli</i> JM109/pSTV28	1	2	1	0.5	1	2	0.5	0.5	0.125	2
<i>E. coli</i> JM109/pSTV- <i>aac</i> WT	16	4	16	1	4	64	8	1	4	4
<i>E. coli</i> JM109/pSTV- <i>aac</i> (TTG→ATG)	32	4	32	1	16	128	8	2	4	4

<sup>a</sup> The MICs for *E. coli* strains were determined with Mueller-Hinton broth preparations containing chloramphenicol (30 μg/ml) and individual aminoglycosides.  
<sup>b</sup> AMK, amikacin; ABK, arbekacin; DIB, dibekacin; GEM, gentamicin; ISP, isopamicin; KAN, kanamycin; NET, netilmicin; SIS, sisomicin; TOB, tobramycin; NEO, neomycin.




FIG. 5. Production of AAC(6')-Iaf in *P. aeruginosa* clinical isolates and *E. coli* transformants used in aminoglycoside susceptibility tests. Each lysate was separated by SDS-15% PAGE and analyzed by Western blotting using polyclonal anti-AAC(6')-Iaf antibodies. The positions of nonspecifically reacting protein bands serving as loading controls are indicated by asterisks. (A) Partial sequences of the *aac(6')-Iaf* gene and its promoter region on pSTV-*aac*WT and pSTV-*aac*(TTG→ATG) and of the corresponding peptides. The putative wild-type initiation codon is shown in boldface type. The initiation codon altered to ATG is boxed. The N-terminal sequence of native AAC(6')-Iaf, as determined by the Edman degradation method, is underlined. (B) Expression of AAC(6')-Iaf in *P. aeruginosa* clinical isolates IMCJ798 and IMCJ799. (C) Expression of AAC(6')-Iaf in *E. coli* JM109 carrying pSTV28 (lane 1; empty vector), pSTV-*aac*WT (lane 2; TTG), and pSTV-*aac*(TTG→ATG) (lane 3; ATG).

(Table 3). To determine whether *aac(6')-Iaf* mediates aminoglycoside resistance, the MICs of various aminoglycosides were assessed using *E. coli* JM109 transformants carrying pSTV-*aac*WT or pSTV-*aac*(TTG→ATG). pSTV-*aac*WT includes both *aac(6')-Iaf* and its 185-bp upstream region from IMCJ798. By using *E. coli* JM109, the *aac(6')-Iaf* gene was expressed utilizing its native promoter and initiation codon. In pSTV-*aac*(TTG→ATG), the putative initiation codon TTG was replaced with ATG, as shown in the nucleotide sequences in Fig. 5A, to solve the problem of low-level expression in *E. coli* caused by a rare initiation codon, as described previously (9, 31). As shown in Table 3, the aminoglycoside resistance profile for *E. coli* JM109 carrying pSTV-*aac*WT or pSTV-*aac*(TTG→ATG) was correlated with those for IMCJ798 and IMCJ799. For the *E. coli* transformants, effective increases of MICs of the same aminoglycosides to which IMCJ798 and IMCJ799 exhibited resistance, AMK, DIB, ISP, KAN, NET, and TOB, were observed. Furthermore, MICs of five of the six above-listed aminoglycosides increased more than twofold for JM109 carrying pSTV-*aac*(TTG→ATG) compared those for JM109 carrying pSTV-*aac*WT. To confirm whether the initiation codon of *aac(6')-Iaf* is TTG, N-terminal sequencing of the native AAC(6')-Iaf protein was performed. The native protein was purified from IMCJ798 by using an affinity column with polyclonal anti-AAC(6')-Iaf rabbit IgG coupled to Sepharose. The molecular mass of purified native AAC(6')-Iaf, as determined by 15% PAGE, corresponded to the estimated size of approximately 21 kDa. The N-terminal sequence of AAC(6')-Iaf was found to be MDYSI (Fig. 5A). Additionally, AAC(6')-Iaf production in IMCJ798, IMCJ799, and *E. coli* JM109 transformants was confirmed by Western blot analysis using polyclonal anti-AAC(6')-Iaf IgG (Fig. 5B and C). The production level of AAC(6')-Iaf in JM109 carrying pSTV-

*aac*(TTG→ATG) increased 2.4-fold compared to that in JM109 carrying pSTV-*aac*WT, whereas the intensities of cross-reacting protein bands were unchanged (Fig. 5B). This increase was similar to results observed previously for the 6-hydroxy-D-nicotine oxidase gene carrying TTG as an initiation codon (31). These results demonstrate that the ORF of *aac(6')-Iaf* initiates from TTG and that *aac(6')-Iaf* plays a crucial role in aminoglycoside resistance in *P. aeruginosa* IMCJ798 and IMCJ799.

**Acetylation activity of AAC(6')-Iaf.** To examine the biochemical properties of AAC(6')-Iaf in aminoglycoside resistance, acetylation activities against various aminoglycosides were assayed by TLC using native AAC(6')-Iaf. TLC analyses showed that all aminoglycosides with an amino group at the 6' position were acetylated by native AAC(6')-Iaf in the presence of acetyl-CoA (Fig. 6). Commercially available GEM is a mixture of derivatives of GEM, such as GEM C1, C1a, C2, and




FIG. 6. Analysis of acetylated aminoglycosides by TLC. Native AAC(6')-Iaf and various aminoglycosides were incubated in the absence (-) or presence (+) of acetyl-CoA. LIV, lividomycin A. The arrow indicates the direction of development.

C2b (41, 44). NEO also consists of derivatives of NEO B and C. In these two reagent mixtures, partially acetylated reagents were observed. Surprisingly, lividomycin A, which has a hydroxyl group at the 6' position, was also a substrate for AAC(6')-Iaf, although only an extremely small amount of AAC activity was detected. This partial acetylation of lividomycin A suggests that AAC(6')-Iaf may have acetylation activities for an alternate amino group in the aminoglycoside molecule. These findings indicate that *aac(6')-Iaf* encodes a functional aminoglycoside 6'-N-acetyltransferase that effectively modifies the amino groups at the 6' positions of aminoglycosides in vitro. However, *E. coli* JM109 carrying pSTV-*aac*WT, expressing exogenous AAC(6')-Iaf, did not show reduced susceptibility to ABK, GEM, or NEO (Table 3). *E. faecium* producing AAC(6')-Ii is susceptible to NEO even though AAC(6')-Ii acetylates NEO (48). ABK and NEO were shown previously to retain their antibiotic effects on an ABK-resistant actinomycete strain, even after they were acetylated at the 6' positions by AAC(6') enzymes (50). These results suggest that the acetylation of ABK and NEO at the 6' positions does not affect the antimicrobial activities of these drugs. The antimicrobial activity retained after treatment with AAC(6')-Iaf may be due to residual unacetylated ABK or NEO. GEM derivatives C1 and C2b carry methyl groups at the 6' positions, and they may be refractory to AAC(6')-I enzymes. Further work is needed to determine the detailed biochemical properties of AAC(6')-Iaf.

#### ACKNOWLEDGMENTS

We are grateful to Kayo Shimada and Tomoko Kuwahara for molecular epidemiological analyses of clinical isolates. We thank Shizuko Iyobe (Kitasato University, Sagami, Japan) for providing the *P. aeruginosa* GN17203 strain. We also thank Michael S. Patrick for revising the manuscript carefully.

This study was supported in part by the Ministry of Health, Labor and Welfare of Japan (grants H18-Shinko-011 and H21-Shinko-008 for genotyping, phenotyping, and functional analyses and H19-shinko-001 for molecular epidemiology).

#### REFERENCES

- Ahmed, A. M., T. Nakagawa, E. Arakawa, T. Ramamurthy, S. Shinoda, and T. Shimamoto. 2004. New aminoglycoside acetyltransferase gene, *aac(3)-Id*, in a class 1 integron from a multiresistant strain of *Vibrio fluvialis* isolated from an infant aged 6 months. *J. Antimicrob. Chemother.* 53:947-951.
- Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25:3389-3402.
- Altschul, S. F., J. C. Wootton, E. M. Gertz, R. Agarwala, A. Morgulis, A. A. Schaffer, and Y. K. Yu. 2005. Protein database searches using compositionally adjusted substitution matrices. *FEBS J.* 272:5101-5109.
- Azucena, E., and S. Mobashery. 2001. Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. *Drug Resist. Updat.* 4:106-117.
- Bissonnette, L., and P. H. Roy. 1992. Characterization of In0 of *Pseudomonas aeruginosa* plasmid pVS1, an ancestor of integrons of multiresistance plasmids and transposons of gram-negative bacteria. *J. Bacteriol.* 174:1248-1257.
- Burk, D. L., N. Ghuman, L. E. Wybenga-Groot, and A. M. Berghuis. 2003. X-ray structure of the AAC(6')-II antibiotic resistance enzyme at 1.8 Å resolution; examination of oligomeric arrangements in GNAT superfamily members. *Protein Sci.* 12:426-437.
- Burk, D. L., B. Xiong, C. Breitbach, and A. M. Berghuis. 2005. Structures of aminoglycoside acetyltransferase AAC(6')-II in a novel crystal form: structural and normal-mode analyses. *Acta Crystallogr. D* 61:1273-1279.
- Casse, F., C. Boucher, J. S. Julliot, M. Michel, and J. Denarie. 1979. Identification and characterization of large plasmids in *Rhizobium meliloti* using agarose gel electrophoresis. *J. Gen. Microbiol.* 113:229-242.
- Centron, D., and P. H. Roy. 1998. Characterization of the 6'-N-aminoglycoside acetyltransferase gene *aac(6')-Iq* from the integron of a natural multiresistance plasmid. *Antimicrob. Agents Chemother.* 42:1506-1508.
- Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
- Collis, C. M., and R. M. Hall. 1992. Site-specific deletion and rearrangement of integron insert genes catalyzed by the integron DNA integrase. *J. Bacteriol.* 174:1574-1585.
- Costa, Y., M. Galimand, R. Leclercq, J. Duval, and P. Courvalin. 1993. Characterization of the chromosomal *aac(6')-II* gene specific for *Enterococcus faecium*. *Antimicrob. Agents Chemother.* 37:1896-1903.
- Davis, B. D. 1987. Mechanism of bactericidal action of aminoglycosides. *Microbiol. Rev.* 51:341-350.
- Doi, Y., and Y. Arakawa. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. *Clin. Infect. Dis.* 45:88-94.
- Doi, Y., J. Wachino, K. Yamane, N. Shibata, T. Yagi, K. Shibayama, H. Kato, and Y. Arakawa. 2004. Spread of novel aminoglycoside resistance gene *aac(6')-Iad* among *Acinetobacter* clinical isolates in Japan. *Antimicrob. Agents Chemother.* 48:2075-2080.
- Doi, Y., K. Yokoyama, K. Yamane, J. Wachino, N. Shibata, T. Yagi, K. Shibayama, H. Kato, and Y. Arakawa. 2004. Plasmid-mediated 16S rRNA methylase in *Serratia marcescens* conferring high-level resistance to aminoglycosides. *Antimicrob. Agents Chemother.* 48:491-496.
- Galimand, M., P. Courvalin, and T. Lambert. 2003. Plasmid-mediated high-level resistance to aminoglycosides in *Enterobacteriaceae* due to 16S rRNA methylation. *Antimicrob. Agents Chemother.* 47:2565-2571.
- Grundmann, H., C. Schneider, D. Hartung, F. D. Daschner, and T. L. Pitt. 1995. Discriminatory power of three DNA-based typing techniques for *Pseudomonas aeruginosa*. *J. Clin. Microbiol.* 33:528-534.
- Hall, R. M., H. J. Brown, D. E. Brookes, and H. W. Stokes. 1994. Integrons found in different locations have identical 5' ends but variable 3' ends. *J. Bacteriol.* 176:6286-6294.
- Hall, R. M., and C. M. Collis. 1995. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. *Mol. Microbiol.* 15:593-600.
- Hall, R. M., and C. M. Collis. 1998. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. *Drug Resist. Updat.* 1:109-119.
- Hamano, Y., Y. Hoshino, S. Nakamori, and H. Takagi. 2004. Overexpression and characterization of an aminoglycoside 6'-N-acetyltransferase with broad specificity from an epsilon-poly-L-lysine producer, *Streptomyces albulus* IFO14147. *J. Biochem.* 136:517-524.
- Hannecart-Pokorni, E., F. Depuydt, L. De Wit, E. van Bossuyt, J. Content, and R. Vanhoof. 1997. Characterization of the 6'-N-aminoglycoside acetyltransferase gene *aac(6')-II* [sic] associated with a *sulI*-type integron. *Antimicrob. Agents Chemother.* 41:314-318. (Author's correction, 42:485, 1998.)
- Head, N. E., and H. Yu. 2004. Cross-sectional analysis of clinical and environmental isolates of *Pseudomonas aeruginosa*: biofilm formation, virulence, and genome diversity. *Infect. Immun.* 72:133-144.
- Kado, C. I., and S. T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. *J. Bacteriol.* 145:1365-1373.
- Kato, T., Y. Sato, S. Iyobe, and S. Mitsuhashi. 1982. Plasmid-mediated gentamicin resistance of *Pseudomonas aeruginosa* and its lack of expression in *Escherichia coli*. *Antimicrob. Agents Chemother.* 22:358-363.
- Kirikae, T., Y. Mizuguchi, and Y. Arakawa. 2008. Investigation of isolation rates of *Pseudomonas aeruginosa* with and without multidrug resistance in medical facilities and clinical laboratories in Japan. *J. Antimicrob. Chemother.* 61:612-615.
- Larkin, M. A., G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, H. McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J. D. Thompson, T. J. Gibson, and D. G. Higgins. 2007. Clustal W and Clustal X version 2.0. *Bioinformatics* 23:2947-2948.
- Levesque, C., L. Piche, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. *Antimicrob. Agents Chemother.* 39:185-191.
- Liu, S. L., A. Hessel, and K. E. Sanderson. 1993. Genomic mapping with I-Ceu I, an intron-encoded endonuclease specific for genes for ribosomal RNA, in *Salmonella* spp., *Escherichia coli*, and other bacteria. *Proc. Natl. Acad. Sci. USA* 90:6874-6878.
- Mauch, L., V. Bichler, and R. Brandsch. 1990. Functional analysis of the 5' regulatory region and the UUG translation initiation codon of the *Arthrobacter oxidans* 6-hydroxy-D-nicotinase gene. *Mol. Gen. Genet.* 221:427-434.
- Miller, G. H., F. J. Sabatelli, R. S. Hare, Y. Glupczynski, P. Mackey, D. Shlaes, K. Shimizu, K. J. Shaw, et al. 1997. The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? *Clin. Infect. Dis.* 24(Suppl. 1):S46-S62.
- Neuwald, A. F., and D. Landsman. 1997. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. *Trends Biochem. Sci.* 22:154-155.
- Poirrel, L., O. Menuteau, N. Agoli, C. Cattoen, and P. Nordmann. 2003. Outbreak of extended-spectrum  $\beta$ -lactamase VEB-1-producing isolates of